Comparative Pharmacology
Head-to-head clinical analysis: LARTRUVO versus NELARABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARTRUVO versus NELARABINE.
LARTRUVO vs NELARABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olaratumab is a recombinant human IgG1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
None Documented
None Documented
Terminal elimination half-life is approximately 11 days (range 4–20 days), supporting a 3-week dosing interval when combined with doxorubicin.
Clinical Note
moderateNelarabine + Digoxin
"Nelarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNelarabine + Digitoxin
"Nelarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNelarabine + Deslanoside
"Nelarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNelarabine + Acetyldigitoxin
"Nelarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Olaratumab is cleared primarily via proteolytic catabolism; no specific renal or biliary excretion studies have been conducted. In patients, only trace amounts are excreted in urine (<1% of dose).
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent